Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – Here’s What Happened

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares gapped down prior to trading on Wednesday . The stock had previously closed at $21.16, but opened at $20.01. Ascentage Pharma Group International shares last traded at $21.6050, with a volume of 276 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Rodman & Renshaw assumed coverage on shares of Ascentage Pharma Group International in a research note on Tuesday, January 13th. They issued a “buy” rating and a $48.00 price objective on the stock. BTIG Research reissued a “buy” rating and issued a $48.00 price objective on shares of Ascentage Pharma Group International in a research note on Monday, April 13th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Ascentage Pharma Group International in a research note on Friday, April 24th. They issued a “buy” rating and a $40.00 price objective on the stock. Finally, China Intl Cap raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, April 6th. Two investment analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $46.67.

Ascentage Pharma Group International Stock Performance

The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57. The company’s fifty day moving average price is $23.95 and its two-hundred day moving average price is $26.94.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) EPS for the quarter. The company had revenue of $24.72 million for the quarter. Analysts forecast that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 earnings per share for the current fiscal year.

Institutional Trading of Ascentage Pharma Group International

A number of hedge funds have recently made changes to their positions in AAPG. XY Capital Ltd raised its stake in shares of Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after purchasing an additional 12,530 shares during the period. UBS Group AG raised its stake in shares of Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares during the period. Hsbc Holdings PLC purchased a new stake in shares of Ascentage Pharma Group International during the second quarter valued at approximately $391,000. Citadel Advisors LLC purchased a new stake in shares of Ascentage Pharma Group International during the third quarter valued at approximately $383,000. Finally, ABC Arbitrage SA purchased a new stake in shares of Ascentage Pharma Group International during the third quarter valued at approximately $204,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical?stage biopharmaceutical company focused on developing small?molecule therapeutics that modulate programmed cell death pathways, including the Bcl?2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.